Merus shares initial findings on MCLA-145 used alone and with Pembrolizumab at the 2024 ASCO conference.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company that is creating innovative treatments…